Evidence map›Paper›PMID 35785159›Full record

ArticleFrontiers in oncology2022

Genomic Features of Solid Tumor Patients Harboring

Yinghuan Dai, Ping Liu, Wenlong He, Lizhen Yang, Yang Ni, Xuejiao Ma, Furong Du, Chao Song, Yang Liu, Yi Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yinghuan DaiDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.
Ping LiuDepartment of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China.
Wenlong HeDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Lizhen YangDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha, China.
Yang NiState Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China.
Xuejiao MaState Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China.
Furong DuState Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China.
Chao SongState Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing, China.
Yang LiuDepartment of Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
Yi SunDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China.
Simcere Pharmaceutical (China) · CNCentral South University · CNSecond Xiangya Hospital of Central South University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fusions of receptor tyrosine kinase (RTK) involving anaplastic lymphoma kinase (

Indexed as

ALKcopy number variantsgene fusionmutational signaturenext generation sequencingNTRKprogrammed death ligand 1ROS1

Identifiers

PMID35785159
PMCPMC9243239
OpenAlexW4282984371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.